Analyst forecasts potential Novo Nordisk upgrade in strong second quarter outlook
Novo Nordisk is expected to stay on the tracks laid in the first quarter, when the pharmaceutical firm also raised its 2022 expectations significantly.
by marketwire, translated by daniel pedersen
On Aug. 4, Novo Nordisk will reveal its second quarter figures, and Jyske Bank analyst Henrik Hallengreen Laustsen spies a guidance opportunity for the firm.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Danish life science firms boosted by currency tailwind
For subscribers
Wegovy celebrates first birthday with subdued cheers
For subscribers
